MORGANTI, STEFANIA
MORGANTI, STEFANIA
Universita' degli Studi di MILANO
I diritti dei morenti in diversi setting di cura al tempo del Covid-19. Uno studio retrospettivo trasversale sulle opinioni degli operatori sanitari.
2023 P. Borsellino, L. Forni, M. Gallucci, A. Cozzolino, S. Morganti, A. Piga, R. Causarano, C. Clerici, S. Fucci, B. Lissoni, P. Pilatri, V. Pocar, S. Salardi, B. Tessadori
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist
2022 P. Zagami, S. Morganti, P. Tarantino, G. Curigliano
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials
2022 A. de Sire, L. Lippi, K. Venetis, S. Morganti, E. Sajjadi, C. Curci, A. Ammendolia, C. Criscitiello, N. Fusco, M. Invernizzi
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
2022 S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022 S. Morganti, A. Marra, E. Crimini, P. D'Amico, P. Zagami, G. Curigliano
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
2021 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, S. Gandini, A. Esposito, G. Curigliano
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
2021 A. Marra, D. Generali, P. Zagami, V. Cervoni, S. Gandini, S. Venturini, S. Morganti, R. Passerini, R. Orecchia, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management
2021 K. Venetis, R. Piciotti, E. Sajjadi, M. Invernizzi, S. Morganti, C. Criscitiello, N. Fusco
Characterization of low HER2 expressions in de-novo metastatic breast cancer
2021 P. Tarantino, E. Nicolo, P. Zagami, F. Giugliano, P. Aliaga, E. Crimini, C. Corti, J. Uliano, S. Morganti, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
2021 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
2021 M. Repetto, E. Crimini, F. Giugliano, S. Morganti, C. Belli, G. Curigliano
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials
2021 P. Trillo Aliaga, D. Trapani, J.L. Sandoval, E. Crimini, G. Antonarelli, G. Vivanet, S. Morganti, C. Corti, P. Tarantino, A. Friedlaender, C. Belli, I. Minchella, M. Locatelli, A. Esposito, C. Criscitiello, G. Curigliano
Antibody–drug conjugates in solid tumors: a look into novel targets
2021 C. Criscitiello, S. Morganti, G. Curigliano
COVID-19 related risk in patients enrolled in early-phase clinical trials
2021 P. D'Amico, P. Trillo, S. Morganti, C. Corti, G. Vivanet, E. Crimini, L. Ascione, P. Tarantino, G. Antonarelli, M. Locatelli, A. Esposito, C. Belli, G. Curigliano
Margetuximab for the treatment of HER2-positive metastatic breast cancer
2021 P. Tarantino, S. Morganti, J. Uliano, F. Giugliano, E. Crimini, G. Curigliano
Clinical development and current role of margetuximab for the treatment of breast cancer
2021 P. Tarantino, J. Uliano, S. Morganti, F. Giugliano, E. Crimini, G. Curigliano
HER2-Low Breast Cancer: Pathological and Clinical Landscape
2020 P. Tarantino, E. Hamilton, S.M. Tolaney, J. Cortes, S. Morganti, E. Ferraro, A. Marra, G. Viale, D. Trapani, F. Cardoso, F. Penault-Llorca, G. Viale, F. Andre, G. Curigliano
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy : A critical review of published data
2020 A. Passaro, I. Attili, S. Morganti, E. Del Signore, L. Gianoncelli, G. Spitaleri, V. Stati, C. Catania, G. Curigliano, F. de Marinis